Viracta Therapeutics to Present at Upcoming Investor Conferences
07 November 2023 - 10:15PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage
precision oncology company focused on the treatment and prevention
of virus-associated cancers that impact patients worldwide, today
announced that Company’s Management will participate in upcoming
investor conferences in November.
Details on the conferences can be found
below:
Stifel 2023 Healthcare Conference Presentation
Date: Wednesday, November 15, 2023
Presentation Time:
10:20 – 10:50 AM ET
Piper Sandler 35th
Annual Healthcare Conference Presentation Date:
Tuesday, November 28,
2023 Presentation
Time: 12:10 – 12:30 PM ET
6th Annual Evercore
ISI HealthCONx Conference Presentation Date: Wednesday,
November 29,
2023 Presentation
Time: 3:25 – 3:45 PM ET
A live webcast of the presentation will be
available on the Investors section of the Viracta website under
"Events and Webcasts" and archived for 90 days.
About Viracta Therapeutics,
Inc.Viracta is a clinical-stage precision oncology company
focused on the treatment and prevention of virus-associated cancers
that impact patients worldwide. Viracta’s lead product candidate is
an all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed or refractory
Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma
and other advanced EBV+ solid tumors. Viracta is also pursuing the
application of its “Kick and Kill” approach in other
virus-related cancers.
For additional information please visit
www.viracta.com.
Investor Relations
Contact:Ashleigh BarretoHead of Investor Relations &
Corporate CommunicationsViracta Therapeutics,
Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024